You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Red Sox Live

2

7

Final

Quanterix, a Lexington company specializing in technology designed for the early detection of diseases, raises $18.5m

Quanterix, a Lexington company specializing in technology designed for the early detection of diseases, said Thursday that it has closed an $18.5 million Series C financing.

Quanterix added that it has also entered a strategic agreement with bioMerieux, a French company that plans to use Quanterix’s Simoa technology to develop specialized tests that focus on infectious diseases.

Continue reading below

As part of the financing, bioMerieux has taken an initial $15 million equity stake in Quanterix.

Participants in the Series C round include existing investors ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures as well as In-Q-Tel, Quanterix said.

Quanterix said it has raised $46.5 million to date.

The company added that its strategic agreement with bioMerieux gives its worldwide exclusive rights to Quanterix’s Simoa technology in clinical laboratories and for industrial applications.

Under the agreement, Quanterix is eligible to receive upfront and milestone payments as well as royalties on future sales. The agreement calls for bioMerieux to take an additional equity stake, contingent upon the achievement of the agreement’s milestones.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week